Used in targeted cancer therapy, particularly for advanced gastric and hepatocellular carcinomas. Inhibits angiogenesis by selectively blocking vascular endothelial growth factor receptor-2 (VEGFR-2), reducing tumor blood supply and growth. Shows efficacy in patients who have failed prior chemotherapy regimens. Investigated in combination with immunotherapies and other anticancer agents to enhance treatment outcomes. Administered orally, allowing for convenient outpatient use in prolonged treatment plans.